Charles Schwab’s Apellis Pharmaceuticals APLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$17.1M Buy
989,143
+24,644
+3% +$427K ﹤0.01% 1756
2025
Q1
$21.1M Sell
964,499
-32,249
-3% -$705K ﹤0.01% 1615
2024
Q4
$31.8M Buy
996,748
+40,386
+4% +$1.29M 0.01% 1423
2024
Q3
$27.6M Buy
956,362
+9,328
+1% +$269K 0.01% 1517
2024
Q2
$36.3M Buy
947,034
+22,472
+2% +$862K 0.01% 1283
2024
Q1
$54.3M Buy
924,562
+20,153
+2% +$1.18M 0.01% 985
2023
Q4
$54.1M Buy
904,409
+25,052
+3% +$1.5M 0.01% 916
2023
Q3
$33.5M Buy
879,357
+50,835
+6% +$1.93M 0.01% 1162
2023
Q2
$75.5M Sell
828,522
-154,987
-16% -$14.1M 0.02% 629
2023
Q1
$64.9M Buy
983,509
+582
+0.1% +$38.4K 0.02% 663
2022
Q4
$50.8M Buy
982,927
+34,168
+4% +$1.77M 0.02% 800
2022
Q3
$64.8M Buy
948,759
+270,358
+40% +$18.5M 0.02% 621
2022
Q2
$30.7M Buy
678,401
+23,093
+4% +$1.04M 0.01% 1082
2022
Q1
$33.3M Buy
655,308
+63,394
+11% +$3.22M 0.01% 1154
2021
Q4
$28M Buy
591,914
+73,103
+14% +$3.46M 0.01% 1314
2021
Q3
$17.1M Buy
518,811
+100,145
+24% +$3.3M 0.01% 1700
2021
Q2
$26.5M Buy
418,666
+14,539
+4% +$919K 0.01% 1354
2021
Q1
$17.3M Buy
404,127
+28,628
+8% +$1.23M 0.01% 1635
2020
Q4
$21.5M Buy
375,499
+6,071
+2% +$347K 0.01% 1357
2020
Q3
$11.1M Buy
369,428
+7,139
+2% +$215K 0.01% 1621
2020
Q2
$11.8M Buy
362,289
+31,206
+9% +$1.02M 0.01% 1538
2020
Q1
$8.87M Buy
331,083
+61,670
+23% +$1.65M 0.01% 1513
2019
Q4
$8.25M Buy
269,413
+8,329
+3% +$255K ﹤0.01% 1750
2019
Q3
$6.29M Buy
261,084
+15,612
+6% +$376K ﹤0.01% 1856
2019
Q2
$6.22M Buy
245,472
+34,064
+16% +$863K ﹤0.01% 1868
2019
Q1
$4.12M Buy
211,408
+18,969
+10% +$370K ﹤0.01% 2066
2018
Q4
$2.54M Sell
192,439
-120
-0.1% -$1.58K ﹤0.01% 2238
2018
Q3
$3.42M Buy
192,559
+20,380
+12% +$362K ﹤0.01% 2238
2018
Q2
$3.79M Buy
172,179
+129,488
+303% +$2.85M ﹤0.01% 2139
2018
Q1
$944K Buy
42,691
+2,949
+7% +$65.2K ﹤0.01% 2533
2017
Q4
$863K Buy
+39,742
New +$863K ﹤0.01% 2555